Credence Research Logo

Home » Biotechnology » Preterm Birth And PROM Testing Market

Preterm Birth and PROM Testing Market By Type (Pelvic Exam, Ultrasound, Biochemical Markers [Interleukin (IL)-6, C-Reactive Protein (CRP), IL-1, IL-2, IL-8, TNF-α, Corticotropin-Releasing Hormone (CRH), Alpha-Fetoprotein (AFP)], Uterine Monitoring, Nitazine Test, Ferning Test, Pooling, PAMG-1 Immunoassay, IGFBP Test, Fetal Fibronectin (fFN), Others); By Application (PROM [Premature Rupture of Membranes], Preterm Labor, Chorioamnionitis) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Report ID: 11294 | Report Format : Excel, PDF

Market Overview

The Preterm Birth And PROM Testing Market size was valued at USD 980.00 million in 2018 to USD 1,344.49 million in 2024 and is anticipated to reach USD 2,559.34 million by 2032, at a CAGR of 8.43% during the forecast period.

REPORT ATTRIBUTE DETAILS
Historical Period 2020-2023
Base Year 2024
Forecast Period 2025-2032
Preterm Birth And PROM Testing Market Size 2024 USD 1,344.49 million
Preterm Birth And PROM Testing Market, CAGR 8.43%
Preterm Birth And PROM Testing Market Size 2032 USD 2,559.34 million

 

The Preterm Birth and PROM Testing Market is gaining momentum due to the rising global incidence of preterm births and associated neonatal complications, which continue to pose significant challenges to maternal and infant health. Increasing awareness among healthcare professionals and expectant mothers about the importance of early diagnosis and intervention is driving the adoption of PROM and preterm birth testing. Technological advancements in biomarker research, non-invasive testing methods, and point-of-care diagnostics are further accelerating market growth by improving test accuracy and accessibility. Government initiatives and healthcare policies promoting maternal and child health screening, especially in developing regions, are expanding the market’s reach. Additionally, the growing penetration of prenatal care services, the rising preference for hospital-based and home-based testing kits, and the ongoing research into predictive testing models are shaping future market dynamics. The convergence of digital health technologies with prenatal diagnostics also presents new opportunities for innovation and broader implementation across healthcare systems.

The Preterm Birth and PROM Testing Market demonstrates strong geographical diversity, with North America leading due to advanced healthcare infrastructure and high awareness. Europe follows closely, driven by standardized prenatal screening and supportive public health policies. Asia Pacific is the fastest-growing region, fueled by rising birth rates, expanding maternal care services, and growing healthcare investments. Latin America is steadily adopting diagnostic technologies, supported by regional reforms and public-private partnerships. The Middle East is enhancing its prenatal care framework, particularly in GCC countries, while Africa is gradually improving diagnostic reach through global health collaborations. Key players shaping the market include Qiagen N.V., Hologic, Inc., Cooper Surgical Inc., Abbott, Medixbiochemica, Sera Prognostics, Clinical Innovations, Biosynex, NX Prenatal, Inc., and IQ Products, all contributing through product innovation, strategic alliances, and geographic expansion to address the global burden of preterm birth and PROM complications.\

Preterm Birth and PROM Testing Market size

Market Insights

  • The Preterm Birth and PROM Testing Market was valued at USD 980.00 million in 2018, reached USD 1,344.49 million in 2024, and is projected to hit USD 2,559.34 million by 2032, growing at a CAGR of 8.43%.
  • Market growth is fueled by the increasing global prevalence of preterm births, rising maternal age, and heightened awareness about early detection and intervention.
  • Advanced diagnostic technologies, including biomarker-based assays and non-invasive point-of-care testing, are improving test accuracy and clinical outcomes.
  • North America leads the market with strong healthcare infrastructure and clinical adoption, while Asia Pacific shows the fastest growth with a CAGR of 9.9%, supported by rising birth rates and government initiatives.
  • Europe follows with robust implementation of screening protocols and supportive public health policies; Latin America is progressing through healthcare reforms and partnerships.
  • The Middle East is enhancing maternal care systems, especially in GCC countries, and Africa is expanding diagnostic access through mobile clinics and global collaborations.
  • Key players include Qiagen N.V., Hologic, Inc., Cooper Surgical Inc., Abbott, Medixbiochemica, Sera Prognostics, Clinical Innovations, Biosynex, NX Prenatal, Inc., and IQ Products, driving innovation and global reach.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research Inc.!

Download Sample

Market Drivers

Rising Global Incidence of Preterm Births and PROM Cases

The Preterm Birth and PROM Testing Market is strongly driven by the growing prevalence of preterm labor and premature rupture of membranes (PROM) worldwide. Increasing maternal age, chronic health conditions, and lifestyle-related factors are contributing to a higher risk of early labor. This trend has intensified the demand for accurate, early-stage diagnostic tools. Hospitals and prenatal care centers are focusing more on timely interventions to improve neonatal outcomes. Governments and health agencies are pushing for better screening protocols to reduce complications. This continuous rise in clinical cases is fueling the market’s expansion across both developed and developing regions.

  • For instance, Abbott Laboratories has developed rapid biomarker-based PROM testing kits that are widely used in hospitals to enable early detection and intervention, supporting improved neonatal outcomes.

Advancements in Diagnostic Technologies and Biomarker Research

The development of biomarker-based testing methods is a key driver for the Preterm Birth and PROM Testing Market. These advanced tests offer higher sensitivity and specificity, enabling early detection of complications and improved clinical decision-making. Innovations in point-of-care testing devices and non-invasive diagnostic solutions have enhanced usability in outpatient and remote settings. The integration of molecular diagnostics and real-time analytics is improving test accuracy. These improvements are leading to faster diagnoses and reduced hospital readmissions. Healthcare providers are increasingly adopting these technologies to enhance maternal-fetal health management protocols.

  • For instance, Qiagen’s PartoSure test kit, which detects placental alpha microglobulin-1 (PAMG-1) levels in vaginal fluid, received FDA approval in April 2018 and can rapidly evaluate the risk of premature birth in women with symptoms of preterm labor, offering high sensitivity and specificity at the point of care.

Increased Awareness and Focus on Maternal-Fetal Health

Public health campaigns and educational programs targeting maternal and neonatal care are contributing significantly to market growth. The Preterm Birth and PROM Testing Market is benefiting from heightened awareness of the risks associated with delayed diagnosis and untreated complications. More women are undergoing routine prenatal screenings, especially in urban healthcare facilities. Healthcare professionals are also more proactive in recommending PROM and preterm labor tests. Insurance coverage for prenatal testing is expanding in various regions. The push for improved healthcare outcomes is making early testing a standard part of prenatal care.

Government Support and Expanding Healthcare Access in Emerging Markets

The growing investment in maternal healthcare infrastructure across emerging economies is playing a major role in driving the Preterm Birth and PROM Testing Market. National health schemes and global health organizations are funding diagnostic initiatives and expanding access to prenatal services. Rural healthcare programs now include early detection strategies for preterm birth risks. Local governments are encouraging the use of cost-effective point-of-care testing devices in public health systems. International collaborations are introducing new screening protocols in underserved areas. The market is gaining traction as healthcare access improves across low- and middle-income countries.

 Market Trends

Growing Adoption of Point-of-Care and Non-Invasive Testing Solutions

The Preterm Birth and PROM Testing Market is witnessing a shift toward point-of-care and non-invasive testing methods due to their convenience and clinical efficiency. These solutions enable timely detection and diagnosis without requiring complex laboratory infrastructure. Healthcare providers are deploying these tools in both urban and remote care settings to enhance access and speed of diagnosis. Patients prefer these methods for their minimal discomfort and quicker turnaround. Companies are investing in user-friendly, portable devices that meet clinical standards. The trend is aligning with broader efforts to decentralize maternal diagnostics and improve early detection.

  • For instance, Sera Prognostics’ PreTRM blood test offers non-invasive early risk assessment for preterm birth, supported by Medicare reimbursement.

Rising Integration of Digital Health and Predictive Analytics

Digital health technologies are increasingly influencing the Preterm Birth and PROM Testing Market, with growing use of predictive analytics and data-driven platforms. Wearable health devices, electronic medical records, and AI-enabled tools are improving risk assessment and decision-making for clinicians. Data integration is allowing real-time monitoring of maternal health indicators, supporting timely interventions. Developers are incorporating advanced algorithms to analyze patient data for early risk signals. Digital platforms are streamlining workflows and reducing delays in care. This trend is enhancing clinical outcomes while improving operational efficiency in prenatal care.

  • For instance, Ultrasound AI Inc. received its first patent in March 2022 for Preterm AI, a software platform that integrates ultrasound imaging with artificial intelligence to predict premature birth, enabling earlier and more accurate clinical interventions.

Expansion of Prenatal Screening Programs Across Emerging Economies

Emerging markets are scaling up prenatal screening programs, creating new opportunities within the Preterm Birth and PROM Testing Market. Governments and health ministries are implementing national guidelines for routine maternal diagnostics. The push for universal access to maternal health services is increasing demand for affordable testing kits. International health organizations are supporting infrastructure development and workforce training to improve diagnostic reach. Companies are responding by tailoring products to local needs and regulatory environments. These developments are boosting test volumes and market penetration across underserved regions.

Product Innovation and Focus on Multiplex Testing Platforms

Innovation in multiplex testing platforms is shaping the future of the Preterm Birth and PROM Testing Market. Developers are introducing combination tests that detect multiple risk markers in a single sample, improving diagnostic efficiency. These platforms reduce testing time and clinical burden, offering greater value to healthcare providers. Laboratories are adopting these technologies to enhance throughput and accuracy. Manufacturers are focusing on improving assay sensitivity and stability. This trend supports precision diagnostics and strengthens the case for early, evidence-based maternal care interventions.

Market Challenges Analysis

Limited Access to Advanced Diagnostic Technologies in Low-Income Regions

The Preterm Birth and PROM Testing Market faces a significant challenge due to uneven access to advanced diagnostic tools, particularly in low- and middle-income countries. Healthcare facilities in these regions often lack the infrastructure and trained personnel required for effective implementation of biomarker-based or point-of-care testing. Many pregnant women remain underserved due to the high cost of diagnostic tools and limited insurance coverage. This access gap leads to delayed or missed diagnoses, increasing maternal and neonatal risk. Market penetration in such regions remains slow despite growing awareness. Addressing this disparity requires strategic investments in healthcare infrastructure and subsidized pricing models.

Regulatory Hurdles and Variability in Clinical Standards

Strict regulatory requirements and varying clinical standards across countries pose a challenge to the growth of the Preterm Birth and PROM Testing Market. Diagnostic product approvals often face lengthy review processes, delaying market entry and commercialization. Differences in testing guidelines and clinical acceptance between regions hinder global standardization of care. Companies must navigate complex compliance landscapes and adapt products to meet country-specific criteria. These factors increase time-to-market and development costs. Standardizing protocols and achieving global regulatory alignment remains a critical need for sustained market growth.

Market Opportunities

Expansion of Prenatal Care in Emerging Economies

The Preterm Birth and PROM Testing Market holds strong growth potential through the expansion of prenatal care services in emerging economies. Governments and international health organizations are increasing investments in maternal health programs, which is driving demand for early diagnostic solutions. Rural and semi-urban healthcare systems are evolving to include routine testing protocols, supported by public health campaigns. Companies that offer affordable, portable, and easy-to-use testing kits can capture significant market share in these regions. Local manufacturing partnerships and distribution networks can enhance accessibility. This creates a favorable environment for scaling diagnostic adoption and improving health outcomes.

Innovation in Multiplex and Home-Based Testing Platforms

The growing interest in multiplex diagnostics and home-based testing presents a major opportunity for the Preterm Birth and PROM Testing Market. Patients and healthcare providers are seeking convenient and time-efficient diagnostic solutions that deliver actionable insights. Multiplex platforms capable of detecting multiple biomarkers in a single test offer improved efficiency and cost-effectiveness. Home-based kits are gaining traction for remote monitoring, especially in telehealth-supported care models. Companies that integrate digital connectivity and user-friendly designs will meet rising consumer expectations. These innovations can expand the market’s reach beyond traditional clinical settings.

Market Segmentation Analysis:

By Type

The Preterm Birth and PROM Testing Market is segmented by type into a diverse range of diagnostic methods. Pelvic exam and ultrasound remain foundational approaches, commonly used in early-stage assessments. Biochemical markers are gaining traction due to their predictive accuracy, including Interleukin (IL)-6, C-Reactive Protein (CRP), IL-1, IL-2, IL-8, TNF-α, Corticotropin-Releasing Hormone (CRH), and Alpha-Fetoprotein (AFP). These markers support early detection of inflammatory responses linked to preterm labor. Other clinical techniques such as uterine monitoring, nitazine test, ferning test, and pooling are frequently used in combination for PROM detection. Advanced immunoassays like PAMG-1 and IGFBP tests, along with fetal fibronectin (fFN), are driving adoption due to their high diagnostic value. The inclusion of multiple test types reflects growing demand for comprehensive and timely prenatal care.

  • For instance, Siemens Healthineers offers fetal fibronectin (fFN) testing, which has been clinically validated to help assess the risk of preterm birth, supporting timely intervention and improved prenatal care.

By Application

By application, the Preterm Birth and PROM Testing Market covers PROM (Premature Rupture of Membranes), preterm labor, and chorioamnionitis. PROM testing dominates due to its direct impact on fetal outcomes and urgency of care. Preterm labor diagnostics are expanding with a focus on early intervention and monitoring strategies. Chorioamnionitis, a serious infection risk, also contributes to increased demand for biomarker-based testing. Each application segment highlights the critical role of early and precise diagnosis in maternal-fetal health management. The rising incidence of complications has strengthened clinical reliance on accurate, application-specific diagnostics.

  • For instance, Hologic, Inc. offers the AmniSure® ROM Test, which is widely used in hospitals to quickly and accurately detect PROM, supporting urgent clinical decisions and improving neonatal outcomes.

Preterm Birth and PROM Testing Market segmentation

Segments:

Based on Type

  • Pelvic Exam
  • Ultrasound
  • Biochemical Markers
  • Interleukin (IL)-6
  • C-Reactive Protein (CRP)
  • IL-1, IL-2, IL-8, TNF-α
  • Corticotropin-Releasing Hormone (CRH)
  • Alpha-Fetoprotein (AFP)
  • Uterine Monitoring
  • Nitazine Test
  • Ferning Test
  • Pooling
  • PAMG-1 Immunoassay
  • IGFBP Test
  • Fetal Fibronectin (fFN)
  • Others

Based on Application

  • PROM (Premature Rupture of Membranes)
  • Preterm Labor
  • Chorioamnionitis

Based on Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • South-east Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of the Middle East and Africa

Regional Analysis

North America

The North America Preterm Birth and PROM Testing Market size was valued at USD 374.36 million in 2018 to USD 507.67 million in 2024 and is anticipated to reach USD 965.13 million by 2032, at a CAGR of 8.4% during the forecast period. North America holds the largest market share, driven by a well-established healthcare infrastructure and high awareness of maternal health. The presence of key industry players and strong insurance coverage enhances diagnostic adoption across the U.S. and Canada. Hospitals and specialized clinics are routinely incorporating advanced biomarker-based and non-invasive tests into prenatal care. Government programs and clinical guidelines continue to support early detection and risk screening. The region’s strong regulatory framework ensures the quality and standardization of diagnostic tools.

Europe

The Europe Preterm Birth and PROM Testing Market size was valued at USD 263.52 million in 2018 to USD 347.78 million in 2024 and is anticipated to reach USD 626.15 million by 2032, at a CAGR of 7.7% during the forecast period. Europe accounts for a significant share of the global market, supported by public health initiatives and increasing adoption of evidence-based obstetric care. Countries like Germany, the UK, and France are leading in the implementation of screening protocols. Hospitals and maternal clinics are integrating advanced testing technologies to improve outcomes and reduce neonatal mortality. The market benefits from ongoing research collaborations and investments in healthcare digitalization. Regulatory alignment across the EU enhances the accessibility of diagnostic innovations across member states.

Asia Pacific

The Asia Pacific Preterm Birth and PROM Testing Market size was valued at USD 220.50 million in 2018 to USD 317.09 million in 2024 and is anticipated to reach USD 671.32 million by 2032, at a CAGR of 9.9%, the highest among all regions. Rapid urbanization, improving access to maternal healthcare, and a growing middle class are fueling demand across countries like China, India, and Japan. Governments are expanding national screening programs and improving prenatal infrastructure. Local manufacturers and multinational firms are investing in cost-effective diagnostic solutions tailored for diverse clinical settings. The rise of digital health platforms and telemedicine is increasing access to testing in rural areas. The region’s large population base and rising birth rates continue to support market growth.

Latin America

The Latin America Preterm Birth and PROM Testing Market size was valued at USD 56.06 million in 2018 to USD 76.08 million in 2024 and is anticipated to reach USD 133.26 million by 2032, at a CAGR of 7.3% during the forecast period. Latin America presents a growing opportunity, driven by efforts to improve maternal health outcomes in countries like Brazil, Argentina, and Mexico. Public and private healthcare sectors are working to increase early diagnosis and reduce complications associated with preterm labor. Medical institutions are adopting affordable and accessible diagnostic tools. Strategic partnerships and foreign investment are helping build diagnostic capacity. Awareness programs and targeted training for healthcare providers are enhancing testing adoption.

Middle East

The Middle East Preterm Birth and PROM Testing Market size was valued at USD 40.18 million in 2018 to USD 51.89 million in 2024 and is anticipated to reach USD 89.85 million by 2032, at a CAGR of 7.2% during the forecast period. The Middle East market is expanding due to rising investments in maternal health services and hospital infrastructure. GCC countries, in particular, are prioritizing advanced prenatal care technologies. Increasing incidence of preterm births and growing reliance on private healthcare systems are driving demand. Hospitals and diagnostic centers are incorporating biomarker-based and non-invasive tests. Governments are supporting policy reforms to enhance early detection and reduce infant mortality. The market continues to evolve with regional collaborations and product localization strategies.

Africa

The Africa Preterm Birth and PROM Testing Market size was valued at USD 25.38 million in 2018 to USD 43.97 million in 2024 and is anticipated to reach USD 73.63 million by 2032, at a CAGR of 6.3% during the forecast period. Africa holds a smaller market share but shows growing potential due to international aid and increasing maternal health awareness. Many countries are working to reduce maternal and neonatal mortality through improved diagnostic access. Mobile clinics and point-of-care devices are expanding reach in underserved areas. Collaborations with NGOs and global health organizations are strengthening early screening capabilities. Economic constraints remain a barrier, but demand for scalable and affordable solutions is increasing. The market is gradually transitioning from basic care to more structured diagnostic approaches.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key Player Analysis

  • Qiagen N.V.
  • Hologic, Inc.
  • Cooper Surgical Inc.
  • Abbott
  • Medixbiochemica
  • Sera Prognostics
  • Clinical Innovations, LLC
  • Biosynex
  • NX Prenatal, Inc.
  • IQ Products

Competitive Analysis

The Preterm Birth and PROM Testing Market features a competitive landscape driven by innovation, strategic collaborations, and portfolio diversification. Leading companies such as Qiagen N.V., Hologic, Inc., Abbott, and Cooper Surgical Inc. are focusing on expanding their diagnostic platforms with high-sensitivity biomarker assays and point-of-care testing solutions. Firms are actively investing in R&D to enhance test accuracy and reduce turnaround times. New entrants and specialized biotech companies are targeting niche segments like fetal fibronectin and PAMG-1 testing. Mergers, acquisitions, and licensing agreements remain common strategies to strengthen market presence and regional access. Companies are also leveraging digital technologies and automation to meet growing clinical demand. The market reflects strong competition based on clinical performance, regulatory approvals, and pricing strategies. It continues to evolve as players aim to improve diagnostic value and address unmet needs in maternal-fetal health diagnostics across both developed and emerging economies.

Recent Developments

  • In March 2024, Hologic, Inc. introduced a new point-of-care diagnostic device for PROM (Premature Rupture of Membranes) testing, designed to deliver rapid and accurate results in both hospital and clinical settings.
  • In June 2024, Sera Prognostics launched a predictive test for preterm birth, focusing on early risk assessment to enable personalized maternal care and timely interventions.
  • In February 2024, Cooper Surgical Inc. acquired a biotechnology company specializing in maternal-fetal health diagnostics to expand its prenatal testing portfolio.

Market Concentration & Characteristics

The Preterm Birth and PROM Testing Market is moderately concentrated, with a mix of established diagnostic firms and emerging biotechnology companies driving competition. It is characterized by continuous innovation in biomarker discovery, increasing demand for point-of-care testing, and the shift toward non-invasive, rapid diagnostic solutions. Leading players focus on expanding their product portfolios, securing regulatory approvals, and entering strategic partnerships to strengthen global reach. The market reflects strong clinical relevance, with consistent adoption across hospitals, diagnostic labs, and maternity care centers. Product differentiation is based on sensitivity, specificity, turnaround time, and ease of use. Companies are leveraging advancements in molecular diagnostics and digital health integration to enhance clinical decision-making. Regulatory compliance, pricing strategies, and regional adaptation play a critical role in market success. Growth opportunities remain high in developing regions where healthcare infrastructure is expanding. It continues to evolve in response to rising maternal health awareness and the global need for early detection.

Report Coverage

The research report offers an in-depth analysis based on Type, Application and Region. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

  1. Demand for early and accurate diagnosis of preterm birth and PROM will continue to rise due to increasing global birth complications.
  2. Point-of-care testing solutions will gain more traction in both hospital and home-care settings.
  3. Biomarker-based diagnostic tests will see higher adoption for their predictive accuracy and clinical reliability.
  4. Digital health integration will improve remote monitoring and real-time data access for prenatal care.
  5. Government support and public health initiatives will expand access to prenatal diagnostics in developing regions.
  6. Innovation in multiplex testing platforms will enhance diagnostic efficiency and reduce clinical workload.
  7. Companies will focus on producing cost-effective and portable devices for low-resource settings.
  8. Regulatory harmonization across regions will streamline product approvals and market entry.
  9. Strategic partnerships between global and regional players will accelerate technology distribution.
  10. Awareness campaigns and maternal education programs will boost early testing and routine screening adoption.

CHAPTER NO. 1 :             GENESIS OF THE MARKET           

1.1 Market Prelude – Introduction & Scope

1.2 The Big Picture – Objectives & Vision

1.3 Strategic Edge – Unique Value Proposition

1.4 Stakeholder Compass – Key Beneficiaries

CHAPTER NO. 2 :             EXECUTIVE LENS

2.1 Pulse of the Industry – Market Snapshot

2.2 Growth Arc – Revenue Projections (USD Million)

2.3. Premium Insights – Based on Primary Interviews

CHAPTER NO. 3 :             PRETERM BIRTH AND PROM TESTING MARKET FORCES & INDUSTRY PULSE            

3.1 Foundations of Change – Market Overview
3.2 Catalysts of Expansion – Key Market Drivers
3.2.1 Momentum Boosters – Growth Triggers
3.2.2 Innovation Fuel – Disruptive Technologies
3.3 Headwinds & Crosswinds – Market Restraints
3.3.1 Regulatory Tides – Compliance Challenges
3.3.2 Economic Frictions – Inflationary Pressures
3.4 Untapped Horizons – Growth Potential & Opportunities
3.5 Strategic Navigation – Industry Frameworks
3.5.1 Market Equilibrium – Porter’s Five Forces
3.5.2 Ecosystem Dynamics – Value Chain Analysis
3.5.3 Macro Forces – PESTEL Breakdown

3.6 Price Trend Analysis

3.6.1 Regional Price Trend
3.6.2 Price Trend by product

CHAPTER NO. 4 :             KEY INVESTMENT EPICENTER    

4.1 Regional Goldmines – High-Growth Geographies

4.2 Product Frontiers – Lucrative Product Categories

4.3 Application  Sweet Spots – Emerging Demand Segments

CHAPTER NO. 5: REVENUE TRAJECTORY & WEALTH MAPPING

5.1 Momentum Metrics – Forecast & Growth Curves

5.2 Regional Revenue Footprint – Market Share Insights

5.3 Segmental Wealth Flow – Type  & Application  Revenue

CHAPTER NO. 6 :             TRADE & COMMERCE ANALYSIS              

6.1.        Import Analysis by Region

6.1.1.     Global Preterm Birth and PROM Testing Market Import Revenue By Region

6.2.        Export Analysis by Region

6.2.1.     Global Preterm Birth and PROM Testing Market Export Revenue By Region

CHAPTER NO. 7 :             COMPETITION ANALYSIS            

7.1.        Company Market Share Analysis

7.1.1.     Global Preterm Birth and PROM Testing Market: Company Market Share

7.2.        Global Preterm Birth and PROM Testing Market Company Revenue Market Share

7.3.        Strategic Developments

7.3.1.     Acquisitions & Mergers

7.3.2.     New Product Launch

7.3.3.     Regional Expansion

7.4.        Competitive Dashboard

7.5.    Company Assessment Metrics, 2024

CHAPTER NO. 8 :             PRETERM BIRTH AND PROM TESTING MARKET – BY TYPE SEGMENT ANALYSIS           

8.1.        Preterm Birth and PROM Testing Market Overview by Type Segment

8.1.1.     Preterm Birth and PROM Testing Market Revenue Share By Type

8.1.2.     Preterm Birth and PROM Testing Market Revenue Share By Type

8.2.        Pelvic exam

8.3.        Ultrasound

8.4.        Biochemical Markers

8.4.1      Interleukin (IL)-6

8.4.2      C-Reactive Protein (CRP)

8.4.3      IL-1, IL-2, IL-8, TNF-a

8.4.4      Corticotropin-Releasing Hormone (CRH)

8.4.5      Alpha-fetoprotein (AFP)

8.5         Uterine Monitoring

8.6.        Nitazine Test

8.7.        Ferning Test

8.8.        Pooling

8.9.        PAMG-1 Immunoassay

8.10.      IGFBP Test

8.11       Fetal Fibronectin (fFN)

8.12       Others

CHAPTER NO. 9 :             PRETERM BIRTH AND PROM TESTING MARKET – BY APPLICATION SEGMENT ANALYSIS      

9.1.        Preterm Birth and PROM Testing Market Overview by Application Segment

9.1.1.     Preterm Birth and PROM Testing Market Revenue Share By Application

9.1.2.     Preterm Birth and PROM Testing Market Revenue Share By Application

9.2.        PROM

9.3.        Preterm Labor

9.4.        Chorioamnionitis

CHAPTER NO. 10 :           PRETERM BIRTH AND PROM TESTING MARKET – REGIONAL ANALYSIS           

10.1.      Preterm Birth and PROM Testing Market Overview by Region Segment

10.1.1.  Global Preterm Birth and PROM Testing Market Revenue Share By Region

10.1.2.  Regions

10.1.3.  Global Preterm Birth and PROM Testing Market Revenue By Region

10.1.4.  Global Preterm Birth and PROM Testing Market Revenue By Region

10.1.5.  Type

10.1.6.  Global Preterm Birth and PROM Testing Market Revenue By Type

10.1.7.  Global Preterm Birth and PROM Testing Market Revenue By Type

10.1.8.  Application

10.1.9.  Global Preterm Birth and PROM Testing Market Revenue By Application

10.1.10.               Global Preterm Birth and PROM Testing Market Revenue By Application

CHAPTER NO. 11 :           NORTH AMERICA PRETERM BIRTH AND PROM TESTING MARKET – COUNTRY ANALYSIS      

11.1.      North America Preterm Birth and PROM Testing Market Overview by Country Segment

11.1.1.  North America Preterm Birth and PROM Testing Market Revenue Share By Region

11.2.      North America

11.2.1.  North America Preterm Birth and PROM Testing Market Revenue By Country

11.2.2.  Type

11.2.3.  North America Preterm Birth and PROM Testing Market Revenue By Type

11.2.4.  Application

11.2.5.  North America Preterm Birth and PROM Testing Market Revenue By Application

11.3.      U.S.

11.4.      Canada

11.5.      Mexico

CHAPTER NO. 12 :           EUROPE PRETERM BIRTH AND PROM TESTING MARKET – COUNTRY ANALYSIS           

12.1.      Europe Preterm Birth and PROM Testing Market Overview by Country Segment

12.1.1.  Europe Preterm Birth and PROM Testing Market Revenue Share By Region

12.2.      Europe

12.2.1.  Europe Preterm Birth and PROM Testing Market Revenue By Country

12.2.2.  Type

12.2.3.  Europe Preterm Birth and PROM Testing Market Revenue By Type

12.2.4.  Application

12.2.5.  Europe Preterm Birth and PROM Testing Market Revenue By Application

12.3.      UK

12.4.      France

12.5.      Germany

12.6.      Italy

12.7.      Spain

12.8.      Russia

12.9.   Rest of Europe

CHAPTER NO. 13 :           ASIA PACIFIC PRETERM BIRTH AND PROM TESTING MARKET – COUNTRY ANALYSIS      

13.1.      Asia Pacific Preterm Birth and PROM Testing Market Overview by Country Segment

13.1.1.  Asia Pacific Preterm Birth and PROM Testing Market Revenue Share By Region

13.2.      Asia Pacific

13.2.1.  Asia Pacific Preterm Birth and PROM Testing Market Revenue By Country

13.2.2.  Type

13.2.3.  Asia Pacific Preterm Birth and PROM Testing Market Revenue By Type

13.2.4.  Application

13.2.5.  Asia Pacific Preterm Birth and PROM Testing Market Revenue By Application

13.3.      China

13.4.      Japan

13.5.      South Korea

13.6.      India

13.7.      Australia

13.8.      Southeast Asia

13.9.      Rest of Asia Pacific

CHAPTER NO. 14 :           LATIN AMERICA PRETERM BIRTH AND PROM TESTING MARKET – COUNTRY ANALYSIS

14.1.      Latin America Preterm Birth and PROM Testing Market Overview by Country Segment

14.1.1.  Latin America Preterm Birth and PROM Testing Market Revenue Share By Region

14.2.      Latin America

14.2.1.  Latin America Preterm Birth and PROM Testing Market Revenue By Country

14.2.2.  Type

14.2.3.  Latin America Preterm Birth and PROM Testing Market Revenue By Type

14.2.4.  Application

14.2.5.  Latin America Preterm Birth and PROM Testing Market Revenue By Application

14.3.      Brazil

14.4.      Argentina

14.5.      Rest of Latin America

CHAPTER NO. 15 :           MIDDLE EAST PRETERM BIRTH AND PROM TESTING MARKET – COUNTRY ANALYSIS

15.1.      Middle East Preterm Birth and PROM Testing Market Overview by Country Segment

15.1.1.  Middle East Preterm Birth and PROM Testing Market Revenue Share By Region

15.2.      Middle East

15.2.1.  Middle East Preterm Birth and PROM Testing Market Revenue By Country

15.2.2.  Type

15.2.3.  Middle East Preterm Birth and PROM Testing Market Revenue By Type

15.2.4.  Application

15.2.5.  Middle East Preterm Birth and PROM Testing Market Revenue By Application

15.3.      GCC Countries

15.4.      Israel

15.5.      Turkey

15.6.      Rest of Middle East

CHAPTER NO. 16 :           AFRICA PRETERM BIRTH AND PROM TESTING MARKET – COUNTRY ANALYSIS           

16.1.      Africa Preterm Birth and PROM Testing Market Overview by Country Segment

16.1.1.  Africa Preterm Birth and PROM Testing Market Revenue Share By Region

16.2.      Africa

16.2.1.  Africa Preterm Birth and PROM Testing Market Revenue By Country

16.2.2.  Type

16.2.3.  Africa Preterm Birth and PROM Testing Market Revenue By Type

16.2.4.  Application

16.2.5.  Africa Preterm Birth and PROM Testing Market Revenue By Application

16.3.      South Africa

16.4.      Egypt

16.5.      Rest of Africa

CHAPTER NO. 17 :           COMPANY PROFILES     

17.1.      Qiagen N.V.

17.1.1.  Company Overview

17.1.2.  Product Portfolio

17.1.3.  Financial Overview

17.1.4.  Recent Developments

17.1.5.  Growth Strategy

17.1.6.  SWOT Analysis

17.2.      Hologic, Inc.

17.3.      Cooper Surgical Inc.

17.4.      Abbott

17.5.      Medixbiochemica

17.6.      Sera Prognostics

17.7       Clinical Innovations, LLC

17.8.      Biosynex

17.9.      NX Prenatal, Inc.

17.10     IQ Products

Request Sample

Request Free Sample

We prioritize the confidentiality and security of your data. Our promise: your information remains private.

Ready to Transform Data into Decisions?

Request Your Sample Report and Start Your Journey of Informed Choices

Providing the strategic compass for industry titans.

cr-clients-logos

Frequently Asked Questions

What is the current size of the Preterm Birth And PROM Testing Market?

The market was valued at USD 1,344.49 million in 2024 and is projected to reach USD 2,559.34 million by 2032, showing strong growth potential

What are the key segments within the Preterm Birth And PROM Testing Market?

The market is segmented by type (e.g., ultrasound, biomarkers, fFN) and application (PROM, preterm labor, chorioamnionitis), addressing diverse diagnostic needs across healthcare settings.

What are some challenges faced by the Preterm Birth And PROM Testing Market?

Major challenges include unequal diagnostic access in low-income regions, high testing costs, limited infrastructure, and regulatory complexities that slow product approvals and global market entry.

Who are the major players in the Preterm Birth And PROM Testing Market?

Key players include Qiagen, Hologic, Abbott, Cooper Surgical, Medixbiochemica, and Sera Prognostics, all investing in innovation, global expansion, and maternal health diagnostics.

About Author

Shweta Bisht

Shweta Bisht

Healthcare & Biotech Analyst

Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.

View Profile

Related Reports By Keyword

Neonatal Thermoregulation Market

The Neonatal Thermoregulation Market size was valued at USD 673.8 million in 2024 and is anticipated to reach USD 1,065.85 million by 2032, at a CAGR of 5.9% during the forecast period (2024-2032).

Inhaled Nitric Oxide Delivery Systems Market

The Inhaled Nitric Oxide Delivery Systems Market is projected to grow from USD 302.3 million in 2024 to an estimated USD 615.74 million by 2032, with a compound annual growth rate (CAGR) of 9.3% from 2024 to 2032.

Bronchopulmonary Dysplasia Treatment market

The Bronchopulmonary Dysplasia Treatment market is projected to grow from USD 390.6 million in 2024 to an estimated USD 617.87 million by 2032, with a compound annual growth rate (CAGR) of 5.9% from 2024 to 2032.

Fetal Monitoring Market

The Fetal Monitoring market is projected to grow significantly, with its size expected to increase from USD 4,077.5 million in 2024 to USD 6,498.916 million by 2032, reflecting a Compound Annual Growth Rate (CAGR) of 6% over the forecast period.

Enteral Tube Feeding Formula Market

The global enteral tube feeding formula market is anticipated to grow at a substantial CAGR of 5.1% in the upcoming years. The global enteral tube feeding formula industry is estimated to be worth USD 6548.5 million in 2021 and is expected to be worth USD 8825.88 million by 2028.

Related Reports

NGS Sample Preparation Market

The NGS (Next-Generation Sequencing) Sample Preparation Market was valued at USD 1,412.5 million in 2024 and is projected to reach USD 2,793.9 million by 2032, expanding at a CAGR of 8.9% during the forecast period.

Tuberculosis Treatment Market

The Global Tuberculosis Treatment Market size was valued at USD 1,327.84 million in 2018 to USD 2,100.42 million in 2024 and is anticipated to reach USD 3,504.37 million by 2032, at a CAGR of 6.15% during the forecast period.

Environmental Health & Safety (EHS) Market

The Environmental Health & Safety (EHS) Market size was valued at USD 6982 million in 2024 and is anticipated to reach USD 12733 million by 2032, at a CAGR of 7.8% during the forecast period (2024-2032).

Bioengineering Technology Market

The bioengineering technology market size was valued at USD 26345 million in 2024 and is anticipated to reach USD 93781.9 million by 2032, at a CAGR of 17.2 % during the forecast period (2024-2032).

Plasma Feed Market

The plasma feed market is projected to grow from USD 908.3 million in 2024 to USD 1,918.9 million by 2032, registering a CAGR of 9.8% during the forecast period.

Biofertilizers Market

The Biofertilizers Market size was valued at USD 2674.5 million in 2024 and is anticipated to reach USD 5136.7 million by 2032, at a CAGR of 8.5% during the forecast period.

Synthetic and Bio Thermosets Market

The Synthetic and Bio thermosets Market size was valued at USD 11,195 million in 2024 and is anticipated to reach USD 15,678.2 million by 2032, growing at a CAGR of 4.3% during the forecast period.

Isothermal Nucleic Acid Amplification Technology Market

The Isothermal nucleic acid amplification technology market is projected to grow from USD 623 million in 2024 to an estimated USD 1,259.7 million by 2032, with a compound annual growth rate (CAGR) of 9.2% from 2024 to 2032.

MEA Biologics and Biosimilars Market

The Middle East and Africa (MEA) Biologics and Biosimilars market size was valued at USD 457.69 million in 2018, increased to USD 649.05 million in 2024, and is anticipated to reach USD 1,023.42 million by 2032, at a CAGR of 5.45% during the forecast period.

Neuro Organoids Market

The Neuro Organoids market size was valued at USD 39.70 million in 2018, increased to USD 85.51 million in 2024, and is anticipated to reach USD 420.35 million by 2032, at a CAGR of 20.54% during the forecast period.

Lignin-Based Plastics Market

The Lignin-Based Plastics Market size was valued at USD 1,150.00 million in 2018 to USD 1,353.50 million in 2024 and is anticipated to reach USD 1,983.51 million by 2032, at a CAGR of 4.92% during the forecast period.

Olfactory Sensing ASIC Market

The Global Olfactory Sensing ASIC Market size was valued at USD 188.10 million in 2018 to USD 383.67 million in 2024 and is anticipated to reach USD 1,202.61 million by 2032, at a CAGR of 14.31% during the forecast period.

Purchase Options

The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$4999

To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$5999

The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
$12999

Let us help you

Credence Staff 3

WILLIAM, North America

+1 304 308 1216

Support Staff at Credence Research

KEITH PHILLIPS, Europe

+44 7809 866 263

Lee - CR Sales Staff

LEE VALLANCE, Asia Pacific

+64 22 017 0275

Kieran Jameson

KIERAN JAMESON, Australia

+61 4192 46279

Report delivery within 24 to 48 hours

What people say?

User Review

Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.

Materials Scientist
(privacy requested)

User Review

The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.

Imre Hof
Management Assistant, Bekaert

Trusted By

cr-clients-logos

Request Sample